Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04312633 · ClinicalTrials.gov registry record
Clinical Utility of WATS3D: A 5-Year Prospective Study
A clinical trial of Gastroesophageal Reflux and Barrett Esophagus, sponsored by CDx Diagnostics.
- Recruiting
- Registry status
- 90,000
- Enrollment target
- 1
- Study location
NCT04312633: Recruiting study of Gastroesophageal Reflux and Barrett Esophagus, sponsored by CDx Diagnostics.
NCT04312633 is a study of Gastroesophageal Reflux and Barrett Esophagus that is actively recruiting participants, run by CDx Diagnostics. The registered enrollment target is 90,000 participants, above the 159-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (56504% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04312633, a study of Gastroesophageal Reflux and Barrett Esophagus, is actively recruiting participants, sponsored by CDx Diagnostics.
- RECRUITING
- Registry status
- 90,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food and liquid from your mouth to your stomach). The two methods of sampling are: 1) Using forceps that take biopsies (small tissue samples) from your esophagus, and 2) Using a brush that also takes biopsies from your esophagus.
Primary Outcome
Clinical Utility of WATS3D as determined by how many patients undergo increased surveillance, radiofrequency ablation and placement on PPIs.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Ambulatory Care - Bethpage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90,000 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2027-11-01 |
What NCT04312633 shows while recruiting
NCT04312633 is an observational study that tracks outcomes without assigning an intervention. Its 90,000 participants enrollment target places it among the larger protocols in the corpus, above the 159-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (56504% higher).
The record links to 4 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 0 interventions.
NCT04312633 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04312633 about?
NCT04312633 is a clinical study titled "Clinical Utility of WATS3D: A 5-Year Prospective Study". The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food and liquid from your mouth to your stomach). The two methods of sampling...
What is the current status of trial NCT04312633?
This trial is currently recruiting. The enrollment target is 90,000 participants. The study started on 2020-04-01. Estimated completion is 2027-11-01.
What conditions does trial NCT04312633 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux, Barrett Esophagus, Esophageal Diseases, Esophageal Dysplasia.
Who is sponsoring clinical trial NCT04312633?
This trial is sponsored by CDx Diagnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04312633 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04312633's enrollment target sits among peer trials
90,000 1st of 33 higher than 33 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05701111 · 80,800 participants · NA
Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI